(0)
Regulatory News:
THERACLION (ISIN: FR0010120402; Memo: ALTHE, PEA-PME eligible), an innovative company specializing in ultrasound therapy (using High Intensity Focused Ultrasound or HIFU), announces that Bernard Sabrier and Unigestion, acting on their own behalf, have informed Theraclion that they have crossed the thresholds of 20% and 25% of the company s capital and voting rights. This situation results from the conversion of convertible bonds into shares and is a sign of confidence in Theraclion s capacity for innovation and development.
In addition to the provisions of the French Commercial Code and Theraclion s statutes, Bernard Sabrier s and Unigestion s increase in Theraclion s share capital comes at a time when the company is reaching a level of technological maturity with the development of SONOVEIN S for the non-invasive treatment of varicose veins, the rollout of ECHOPULSE for the treatment of thyroid nodules, and recent announcement in the treatment of breast canc